Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has launched Leo™, a next-generation Simple Western™ system that significantly enhances protein analysis capabilities. The system can process up to 100 samples in a single 3-hour run, delivering 4x higher throughput than the Jess™ system and 5x faster processing than Sally Sue™ and Peggy Sue™ systems.

Leo features enhanced Compass Software with advanced analysis capabilities and improved 21 CFR Part 11 Compliance support. The system offers experimental size, precision, and reproducibility suitable for regulatory submissions. Beta testers have praised Leo's robust performance and versatility across applications including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control, and recombinant protein expression.

Positive

• 4x higher throughput capacity compared to previous Jess™ system
• 5x faster processing times than existing Sally Sue™ and Peggy Sue™ systems
• Improved regulatory compliance with enhanced 21 CFR Part 11 support
• Expanded application capabilities for bioanalytical workflows

Negative

• None.

News Market Reaction

-2.28%

1 alert

-2.28% News Effect

On the day this news was published, TECH declined 2.28%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

MINNEAPOLIS, March 10, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.

Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run, offering 4x the throughput of the Jess™ Simple Western System and 5x faster turn-around-times than Sally Sue™ and Peggy Sue™ Simple Western Systems. Leo also provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies. Additionally, Leo features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance. 

"With Leo, scientists can achieve their development milestones faster and more efficiently, completing studies with fewer runs, operators and instruments," commented Will Geist, President of Bio-Techne's Protein Sciences Segment. "Leo will enable our customers to accelerate their cutting-edge science and bring next generation therapies to market faster."

Early adopters have been thrilled with the power that Leo brings, with beta testers praising the instrument's robust performance, data quality, and wide range of applications, including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control and release assays, recombinant protein expression and more.

Explore Leo's capabilities at bio-techne.com/leo. Data on Leo's performance will be presented at an upcoming webinar. Registration details can be found here.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com 
612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-begins-shipping-leo---a-next-generation-high-throughput-simple-western-system-302395190.html

SOURCE Bio-Techne Corporation

FAQ

What are the key features of Bio-Techne's (TECH) new Leo system?

Leo processes 100 samples in 3 hours, offers 4x higher throughput than Jess system, and includes enhanced Compass Software with improved regulatory compliance features.

How much faster is TECH's Leo system compared to previous models?

Leo is 5x faster than Sally Sue and Peggy Sue systems, and provides 4x higher throughput than the Jess system.

What applications does Bio-Techne's (TECH) Leo system support?

Leo supports targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control, and recombinant protein expression.

How does TECH's Leo system improve regulatory compliance?

Leo features enhanced Compass Software with improved 21 CFR Part 11 Compliance support and provides analytical grade protein quantitation for regulatory submissions.